Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder

NEW YORK, April 01, 2024 -- Axsome Therapeutics, Inc. , a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, announced the...

Related Keywords

New York ,United States ,American ,Darren Opland ,Mark Jacobson ,Nasdaq ,Drug Administration ,Axsome Therapeutics Inc ,American Psychiatric Association ,World Trade Center ,Corporate Communications ,National Comorbidity Survey Replication ,Binge Eating Disorder Using Solriamfetol ,Axsome Therapeutics ,Statistical Manual ,Mental Disorders ,Eating Disorders ,Markets ,